Announcement on Obtaining Government Subsidies
Filed with SSE · · 1 page · Chinese
Bio-Thera Solutions, Ltd. on 6ix
Earlier from Bio-Thera Solutions
- Announcement on Acceptance of Marketing Authorization Application for Vilacita Monoclonal Antibody Injection (BAT5906)
- Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
- Announcement on Convening the Q3 2025 Performance Briefing
- Report for Q3 2025
- Announcement on Voluntary Disclosure of Progress in the Receipt of the Initial Payment from STADA for the Signing of the Licensing and Commercialization Agreement for BAT1806 (Tocilizumab) Injection
Later from Bio-Thera Solutions
- Announcement on Estimated Daily Related Party Transactions in 2026
- Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Sandoz AG for BAT1706 (Bevacizumab) Injection
- Announcement on Voluntary Disclosure of Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Hikma Pharmaceuticals USA Inc. for BAT2206 (Ustekinumab) Injection
- Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization, Production, Supply and Commercialization Agreement with Gedeon Richter Plc. (Richter Gedeon) for BAT2206 (Ustekinumab) Injection
- Announcement on Signing a Project Construction Work Contract by the Wholly-owned Subsidiary and Related Party and Related Party Transactions
Follow Bio-Thera Solutions into a list and get an email when it puts out news.
Follow Bio-Thera Solutions